These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31731456)

  • 1. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas.
    Zajdel M; Rymkiewicz G; Sromek M; Cieslikowska M; Swoboda P; Kulinczak M; Goryca K; Bystydzienski Z; Blachnio K; Ostrowska B; Borysiuk A; Druzd-Sitek A; Walewski J; Chechlinska M; Siwicki JK
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.
    Sromek M; Rymkiewicz G; Paziewska A; Szafron LM; Kulecka M; Zajdel M; Kulinczak M; Dabrowska M; Balabas A; Bystydzienski Z; Chechlinska M; Siwicki JK
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.
    Fischer L; Hummel M; Korfel A; Lenze D; Joehrens K; Thiel E
    Neuro Oncol; 2011 Oct; 13(10):1090-8. PubMed ID: 21803762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
    Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.
    Baraniskin A; Schroers R
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma.
    Hu Y; Zhang Q; Wu Z; Chen K; Xu X; Ma W; Chen B; Jin L; Guan M
    Discov Oncol; 2023 Nov; 14(1):205. PubMed ID: 37971595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.
    Baraniskin A; Kuhnhenn J; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2012 Sep; 109(2):239-44. PubMed ID: 22729947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
    Ma J; Lin Z; Zhang Y; Ding Y; Tang Q; Qian Y; Jin B; Luo RY; Liao WL; Thyparambil S; Han Z; Chou CJ; Schilling J; Li Q; Zhang M; Lin Y; Ma Y; Sylvester KG; Nagpal S; McElhinney DB; Ling XB; Chen B
    Front Immunol; 2024; 15():1343109. PubMed ID: 39144147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the
    Zorofchian S; Lu G; Zhu JJ; Duose DY; Windham J; Esquenazi Y; Ballester LY
    Front Oncol; 2018; 8():382. PubMed ID: 30294590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
    Downs BM; Ding W; Cope LM; Umbricht CB; Li W; He H; Ke X; Holdhoff M; Bettegowda C; Tao W; Sukumar S
    Clin Epigenetics; 2021 May; 13(1):104. PubMed ID: 33952317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
    De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
    Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas.
    Choi JS; Nam DH; Ko YH; Seo JW; Choi YL; Suh YL; Ree HJ
    Am J Surg Pathol; 2003 Jul; 27(7):919-28. PubMed ID: 12826884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
    Ohno M; Matsuzaki J; Kawauchi J; Aoki Y; Miura J; Takizawa S; Kato K; Sakamoto H; Matsushita Y; Takahashi M; Miyakita Y; Ichimura K; Narita Y; Ochiya T
    JAMA Netw Open; 2019 Dec; 2(12):e1916953. PubMed ID: 31808923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma.
    Deng Y; Li Q; Sun J; Ma L; Ding Y; Cai Y; Iliuk A; Chen B; Xie Z; Tao WA
    Analyst; 2023 Jul; 148(15):3594-3602. PubMed ID: 37403840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.